Market revenue in 2023 | USD 215.0 million |
Market revenue in 2030 | USD 691.8 million |
Growth rate | 18.2% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data | 2021 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Australia mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
Rising government investments and private players in mRNA synthesis R&D are expected to boost the demand for relevant raw materials. Hence, several companies are launching innovative products and are partnering with vaccine manufacturers to provide the raw materials required for mRNA synthesis.
Owing to the rising awareness regarding mRNA vaccines in the country, companies are launching dedicated facilities for mRNA vaccine manufacturing, which is expected to boost the demand for raw materials required for mRNA synthesis.
For instance, in August 2022, Moderna, Inc. launched an mRNA vaccine manufacturing facility in Melbourne, the first in the southern hemisphere region. The facility is located at Monash, one of the largest universities in Australia, and is projected to manufacture around 100 million vaccine doses per year for influenza, COVID-19, and other diseases.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia mrna therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia mrna therapeutics market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account